Clinical Trials
20 trialsNCT07552558 2026-06-03
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT03737734 2026-04-06
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Active not recruiting
NCT05837221 2026-02-24
Microbiome in Head and Neck Squamous Cell Carcinoma
University of Colorado, Denver
Recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03886181 2025-12-08
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Terminated
NCT03889899 2025-12-02
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04540588 2025-12-02
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Alpha Tau Medical LTD.
Phase NA Completed
NCT00568490 2025-07-02
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Stanford University
Recruiting
NCT07005115 2025-06-06
Serum Lipid Profile and Lip Squamous Cell Carcinoma
Akdeniz University
Completed
NCT04534127 2025-02-07
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT04068155 2024-11-22
Alpha Radiation Emitters Device for the Treatment of of Malignant Cutaneous Tumors
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT03422536 2024-09-04
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
Phase 2 Completed
NCT05610293 2023-08-16
T1 Squamous Cell Carcinomas of the Lip
Maastricht University Medical Center
Unknown
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT03239834 2021-08-12
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Vigilant Biosciences, Inc.
Completed
NCT01084733 2021-07-14
Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer
University of Kentucky
Completed
NCT00186433 2015-05-27
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Stanford University
Completed
NCT00050388 2008-06-24
Phase II Trial of Allovectin-7® for Head and Neck Cancer
Vical
Phase 3 Completed